No abstract

No abstract

The finding that eluted mesangial IgA and serum IgA from patients with IgA nephropathy had a restricted anionic charge contrasting with normal serum IgA prompted us to study the charge of the kappa and lambda subclasses of IgA. Serum IgA from 11 patients with IgA nephropathy and 11 controls was purified by affinity chromatography by binding to jacalin. The charges of IgA were studied by a novel method. The spectrotype of total IgA was first studied by isoelectric focusing and immunoblotting. IgAλ and IgAκ was further analyzed by reacting with specific monoclonal antibodies. The amount of IgA with different pis was analyzed by computerized densitometry. The anionic :cationic (A: C) ratio of IgA using pi 5.6 as the dividing point was greater in patients (at clinical quiescence and during exacerbation) than in controls (1.67 ± 0.31 versus 1.36 ± 0.27, p < 0.025). IgAλ in both groups was anionic (A:C ratio 2.22 ± 0.77 versus 2.36 ± 0.36) and IgAκ was cationic (A:C ratio 1.15 ± 0.36 versus 1.04 ± 0.39) but no difference in the A:C ratio was demonstrated. The increased A:C ratio in total IgA in patients was due to raised serum IgAλ (κ/λ ratio 1.11 ± 0.14 in patients and 1.51 ± 0.16 in controls, p < 0.01). We had previously shown a predominant mesangial deposition of IgAλ in IgA nephropathy. Animal experiments have revealed the preferential mesangial deposition of immune complexes is related to their anionic charges. Our data of raised anionic IgAλ in IgA nephropathy may be important in determining its selective mesangial binding that could contribute to the immunopathogenesis.

Allergic rhinitis impairs quality of life (QOL). To assess the changes in QOL of patients with perennial allergic rhinitis (PAR) after treatment with Allergic Rhinitis Nose Drops (ARND), 35 patients were divided into 2 groups in a randomized, double-blinded and placebo-controlled study, with a cross-over arrangement over 7 weeks, applying ARND or placebo. Group A (n = 20) started with ARND first for 2 weeks followed by a 3-week washout before placebo for the last 2 weeks, while Group B (n = 15) started with placebo first and finished with ARND after washout. The changes in Clinical Symptoms Score (CSS) and QOL were observed. A decrease in CSS was observed in patients of both groups after treatment with ARND, but no change was observed with the placebo. Group A patients also showed significant improvements in complexion and sleep (P < 0.05 for both) after treatment with ARND, but no change with the placebo. Group B patients showed significant improvements in appetite and digestion (P < 0.01) as well as joy (P < 0.05) after cross-over treatment with ARND, but no change with the placebo. ARND may have a therapeutic effect by relieving clinical symptoms and improving the QOL in patients with PAR.